Definium Therapeutics (NASDAQ:DFTX) Shares Climb 5.3% – Time to Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares shot up 5.3% during trading on Monday. The company traded as high as $38.38 and last traded at $38.08. 1,262,536 shares were traded during trading, a decline of 44% from the average daily volume of 2,263,909 shares. The stock had previously closed at $36.17.

Analysts Set New Price Targets

DFTX has been the topic of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of Definium Therapeutics in a research note on Monday, September 14th. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. JonesTrading raised their target price on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Wells Fargo & Company boosted their target price on Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Finally, Robert W. Baird upped their price target on Definium Therapeutics from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $64.88.

Definium Therapeutics Trading Up 7.2%

The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The stock has a market capitalization of $5.21 billion, a price-to-earnings ratio of -11.31 and a beta of 2.23. The business has a 50 day simple moving average of $41.59 and a 200-day simple moving average of $31.78.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, equities analysts expect that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Insider Activity at Definium Therapeutics

In related news, CEO Robert Barrow sold 19,023 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $37.94, for a total value of $721,732.62. Following the sale, the chief executive officer directly owned 1,494,640 shares of the company’s stock, valued at approximately $56,706,641.60. The trade was a 1.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Definium Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DFTX. Sequoia Financial Advisors LLC acquired a new position in shares of Definium Therapeutics during the second quarter worth about $812,000. WINTON GROUP Ltd acquired a new stake in Definium Therapeutics in the 2nd quarter valued at approximately $240,000. Engineers Gate Manager LP bought a new stake in shares of Definium Therapeutics in the second quarter worth $481,000. Integrated Wealth Concepts LLC bought a new stake in Definium Therapeutics during the 2nd quarter worth about $159,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Definium Therapeutics in the second quarter valued at about $222,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.